Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S369-S372. doi: 10.21037/tlcr.2019.06.05.

Authors

Satomi Tanaka¹, Junji Uchino¹

Affiliation

¹ Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

No abstract available

Publication types

Editorial
Comment